Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that it has successfully completed the process of transitioning to the OTCQB Venture Market. The Company’s common stock begins trading on the OTCQB Venture Market today, June 25, 2025 with the trading symbol, HEPA.

About Hepion Pharmaceuticals

Hepion is a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma.

For further information, please contact:

Hepion Pharmaceuticals
[email protected]

You May Also Be Interested In

• HII’s Newport News Shipbuilding Completes Successful Acceptance Sea Trials of John F. Kennedy (CVN 79)
• Dogecoin Price Prediction: $0.15 Bull Case Would More Than Double DOGE as AlphaPepe $1 Roadmap Talk Targets Bigger Upside
• The King Center and Divine Nine Launch Historic Fundraising Campaign to Preserve Critical History and Amplify Nonviolence365® Ahead of King100